Insights into Gastrointestinal Stromal Tumor Market 2024: Size, Share, Growth, and Trends Analysis

The gastrointestinal stromal tumor market size has grown strongly in recent years. It will grow from $1.18 billion in 2023 to $1.28 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increased awareness and early diagnosis, emergence of targeted therapies, enhanced surgical techniques, development of personalized medicine, improvements in supportive care.

The gastrointestinal stromal tumor market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to continued research and drug development, rise in patient-centric healthcare, integration of precision medicine in clinical practice, increasing access to targeted therapies, expanding genomic profiling capabilities. Major trends in the forecast period include growing collaboration in research and development, advancements in diagnostic technologies, collaborative research and clinical trials, increased focus on early detection and diagnosis, exploration of combination therapies.

Market Overview -
A gastrointestinal stromal tumor (GIST) is a type of rare, non-epithelial tumor that originates in the gastrointestinal (GI) tract. These are most commonly developed in the stomach or the small intestine, but they can occur anywhere along the GI tract, from the esophagus to the rectu*m.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

Growing Incidence Of Stomach Cancer To Boost The Market
The growing incidence of stomach cancer is expected to propel the growth of the gastrointestinal stromal tumor market going forward. Stomach cancer refers to the uncontrolled growth and multiplication of malignant cells in the lining of the stomach. while gastrointestinal stromal tumors (GISTs) can occur in the stomach, they are distinct from stomach cancer. When two separate tumors collide and merge into one, patients with GISTs have been found to have an increased risk of developing additional cancers, including small bowel adenocarcinoma. For instance, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of stomach cancer in the UK is projected to fall by 12% between 2023-2025 and 2038-2040, to 8 cases per 100,000 people on average each year. Therefore, the growing incidence of stomach cancer is driving the growth of the gastrointestinal stromal tumor market.

Competitive Landscape -
Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

Increasing Focus On Drug Approvals To Drive The Revenues
Major companies operating in the gastrointestinal stromal tumor market are innovating new drugs such as QINLOCK (Ripretinib) to meet larger customer bases, more sales, and increased revenue. QINLOCK (Ripretinib) is a prescription medicine used to treat advanced gastrointestinal stromal tumor (GIST). For instance, in March 2021, Zai Lab Ltd, a China-based biotechnology company announced that the National Medical Products Administration (NMPA) of China had approved a new drug QINLOCK (Ripretinib), for the treatment of GIST, an advanced form of gastrointestinal stromal tumor. A prescription drug called QINLOCK (ripretinib) is used to treat advanced gastrointestinal stromal tumors (GIST) in adult patients who have previously been treated with three or more kinase inhibitors, including imatinib.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report
Key Segments -
The gastrointestinal stromal tumor market covered in this report is segmented -
1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.